Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;64(5):3173-3176.
doi: 10.1093/rheumatology/keaf037.

The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit

Affiliations

The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit

Hannah Jethwa et al. Rheumatology (Oxford). .
No abstract available

PubMed Disclaimer

References

    1. Najm A, Goodyear CS, McInnes IB, Siebert S. Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy. Nat Rev Rheumatol 2023;19:153–65. - PubMed
    1. Mease PJ, Genovese MC, Weinblatt ME et al. Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate. Arthritis Rheumatol (Hoboken, NJ) 2018;70:1778–89. - PMC - PubMed
    1. Haberman RH, , CastilloR, , Scher JU. Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination. Rheumatology (Oxford, England) 2021;60:e225–6. - PMC - PubMed
    1. Abignano G, Fadl N, Merashli M et al. A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: data from the Leeds Combined Psoriatic Service. J Ame Acad Dermatol 2019;80:1796–8. - PubMed
    1. Shurey M, Yip A, Ziouzina O, Chan J, Dutz JP. Combination therapy with tofacitinib and IL-12/23, IL-23, or IL-17A inhibition for the treatment of refractory psoriatic arthritis: a case series. JCR J Clin Rheumatol 2022;28:e626–e8. - PubMed